Microbiome-Based Stratification and Lactulose Therapy for Infection Prevention in Advanced Liver Disease
SUMMARY
Improved survival and reduced systemic infections in advanced liver disease patients by expanding gut Bifidobacteria through lactulose administration, leveraging metabolomic profiling to stratify candidates for targeted microbiome-based therapeutics
The Unmet Need: High infection rates and mortality in advanced liver disease with limited targeted microbiome therapies
- Patients with advanced liver disease experience a significant burden from systemic infections, with approximately 20.6% of individuals with cirrhosis developing infections that cause 30-50% of related deaths. Current treatment strategies predominantly rely on broad-spectrum antibiotics, which disrupt the gastrointestinal microbiome and contribute to the emergence of antibiotic-resistant pathogens, thereby increasing vulnerability to recurrent infections.
-
The increasing recognition of the gut microbiome’s role in health and disease has catalyzed broader research and industry interest in microbiome-based therapeutics, establishing an opportunity for synbiotic approaches that selectively enhance beneficial commensal bacteria and their metabolites to improve clinical outcomes in hepatology.
The Proposed Solution: Lactulose-driven expansion of gut Bifidobacteria combined with metabolomic-guided patient stratification for infection reduction and survival improvement
- The technology comprises a diagnostic methodology employing metabolomic and metagenomic profiling of short-chain fatty acids and bile acids to identify advanced liver disease patients likely to benefit from microbiome interventions, and therapeutic administration of lactulose as a prebiotic to selectively expand Bifidobacteria populations within the gut microbiome. This approach differs from conventional antibiotic therapies by promoting microbial ecosystem restoration rather than broad microbial eradication. Clinical observational studies revealed significant associations between lactulose-mediated Bifidobacteria expansion, reduced antibiotic resistance gene prevalence, lower incidence of spontaneous bacterial peritonitis and bacteremia, and improved overall patient survival.
ADVANTAGES
-
Improved survival in advanced liver disease patients
-
Targeted synbiotic modulation of gut microbiome
-
Reduction in antibiotic-resistant pathogen burden
-
Metabolomic-based patient stratification
-
Non-antibiotic therapeutic alternative
-
Potential for integration with existing hepatology care
APPLICATIONS
-
Prevention of spontaneous bacterial peritonitis in cirrhosis
-
Reduction of bacteremia in hospitalized liver disease patients
-
Adjunctive therapy for hepatic encephalopathy management
PUBLICATIONS